Neuroendocrine tumors of the appendix, colon, and rectum
J Hrabe - Surgical Oncology Clinics, 2020 - surgonc.theclinics.com
Neuroendocrine tumors (NETs) encompass a range of pathologies and behaviors, ranging
from indolent tumors often discovered incidentally, to poorly differentiated and aggressive …
from indolent tumors often discovered incidentally, to poorly differentiated and aggressive …
[HTML][HTML] Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management
B Altieri, C Di Dato, C Martini, C Sciammarella… - Cancers, 2019 - mdpi.com
Bone represents a common site of metastases for several solid tumors. However, the ability
of neuroendocrine neoplasms (NENs) to localize to bone has always been considered a …
of neuroendocrine neoplasms (NENs) to localize to bone has always been considered a …
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
L Bodei, MS Kidd, A Singh, WA Van Der Zwan… - European journal of …, 2018 - Springer
Background Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor
(SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy …
(SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy …
Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with …
S Ezziddin, M Attassi, CJ Yong-Hing… - Journal of nuclear …, 2014 - Soc Nuclear Med
Outcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP
NET) after peptide receptor radionuclide therapy (PRRT) are still limited, especially with …
NET) after peptide receptor radionuclide therapy (PRRT) are still limited, especially with …
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in …
Background Peptide receptor radionuclide therapy (PRRT) is an effective method for treating
neuroendocrine tumors (NETs). It is limited, however, in the prediction of individual tumor …
neuroendocrine tumors (NETs). It is limited, however, in the prediction of individual tumor …
Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
A Sabet, K Ezziddin, UF Pape… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy
(PRRT). The aim of this study was to investigate the incidence, severity, and reversibility of …
(PRRT). The aim of this study was to investigate the incidence, severity, and reversibility of …
Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
A Sabet, K Dautzenberg, T Haslerud, A Aouf… - European journal of …, 2015 - Springer
Purpose Increasing evidence supports the value of peptide receptor radionuclide therapy
(PRRT) in patients with metastatic neuroendocrine tumours (NET), but there are limited data …
(PRRT) in patients with metastatic neuroendocrine tumours (NET), but there are limited data …
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
A Sabet, T Haslerud, UF Pape, A Sabet… - European journal of …, 2014 - Springer
Purpose We assessed the outcome and toxicity of salvage therapy (repeat treatment) with
177 Lu-octreotate and high cumulative activities in patients with metastatic …
177 Lu-octreotate and high cumulative activities in patients with metastatic …
Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system
S Ezziddin, L Adler, A Sabet, TD Pöppel… - Journal of Nuclear …, 2014 - Soc Nuclear Med
The tumor proliferation marker, Ki-67 index, is a well-established prognostic marker in
gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging …
gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging …
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
A Sabet, K Ezziddin, UF Pape, K Reichman… - European journal of …, 2014 - Springer
Purpose Renal radiation during peptide receptor radionuclide therapy (PRRT) may result in
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …